Acute exacerbations of chronic bronchitis: a pharmacoeconomic review of antibacterial use

PharmacoEconomics
Stephen MorrisDebra E Irwin

Abstract

Chronic bronchitis is a common problem affecting a large proportion of the adult population. People with chronic bronchitis are subject to recurrent attacks of bronchial inflammation called acute exacerbations of chronic bronchitis (AECBs). In patients with AECBs, symptoms may worsen due to a bacterial infection; the exacerbation is then known as an acute bacterial exacerbation of chronic bronchitis (ABECB). ABECBs are thought to be controllable through the use of antibacterial agents. In this paper we review current evidence on the cost of chronic bronchitis and AECBs, the cost effectiveness of antibacterials in the management of ABECB, and the factors that may affect the cost-effectiveness of antibacterials in the management of ABECB. We find that the number of economic evaluations conducted in this area is small. Of the few economic evaluations that have been conducted there has been only one prospective economic evaluation based on a clinical trial. The remainder are simple decision analysis-based modelling studies or retrospective database studies. Our principle findings are as follows: a key factor affecting the cost-effective use of antibacterials in the management of ABECB is the definitive diagnosis of the condition. U...Continue Reading

References

Jun 1, 1992·The American Review of Respiratory Disease·P W JonesP Littlejohns
Oct 3, 1987·British Medical Journal·J CockburnR W Sanson-Fisher
Feb 1, 1987·Annals of Internal Medicine·N R AnthonisenN A Nelson
Aug 1, 1995·American Journal of Respiratory and Critical Care Medicine·S E LapinskyA S Slutsky
Mar 22, 1995·JAMA : the Journal of the American Medical Association·S SaintD Grady
May 1, 1996·The Journal of International Medical Research·A Branthwaite, J C Pechère
Aug 1, 1996·The European Respiratory Journal·M WoodheadT Schaberg
May 8, 1995·PharmacoEconomics·D FeenyG W Torrance
May 1, 1999·Antimicrobial Agents and Chemotherapy·T A DaviesP C Appelbaum
May 13, 1999·Clinical Therapeutics·M S NiedermanR Popovian
Mar 17, 2000·The Journal of Antimicrobial Chemotherapy·P Nicolson, P Anderson
Apr 5, 2000·Seminars in Respiratory Infections·R F Grossman
Mar 17, 2001·The Journal of Antimicrobial Chemotherapy·F BarchiesiM A Viviani
Feb 15, 2002·Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases·A M LoveringD Irwin

❮ Previous
Next ❯

Citations

Dec 1, 2010·Journal of Chemotherapy·F BlasiUNKNOWN GIARIR
May 13, 2017·Revue des maladies respiratoires·C Gut-Gobert
Mar 17, 2017·Journal of Chemotherapy·Francesco BlasiUNKNOWN On behalf of the *MASTER working group

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antimicrobial Resistance

Antimicrobial resistance poses a significant threat to the continued successful use of antimicrobial agents for the treatment of bacterial infections.

Allergy & Infectious Diseases

Allergies result from the hyperreactivity of the immune system to some environmental substance and can be life-threatening. Infectious diseases are caused by organisms including bacteria, viruses, fungi and parasites. They can be transmitted different ways, such as person-to-person. Here is the latest research on allergy and infectious diseases.

Antimicrobial Resistance (ASM)

Antimicrobial resistance poses a significant threat to the continued successful use of antimicrobial agents for the treatment of bacterial infections.

Allergy & Infectious Diseases (ASM)

Allergies result from the hyperreactivity of the immune system to some environmental substance and can be life-threatening. Infectious diseases are caused by organisms including bacteria, viruses, fungi and parasites. They can be transmitted different ways, such as person-to-person. Here is the latest research on allergy and infectious diseases.